StockData

Fulgent Genetics vs GeneDx

FLGT and WGS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FLGT and WGS compare

GeneDx is the larger company, worth 2.3 times as much as Fulgent Genetics ($1.5B against $666M).

GeneDx grew revenue faster over the last twelve months (25.4% versus 6.8% for Fulgent Genetics).

GeneDx keeps more of each dollar of sales as profit, with a net margin of −23.4% compared with −26.0% at Fulgent Genetics.

Fulgent Genetics scores higher on the StockData Score (7 against 6 for GeneDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFLGTWGS
Size and price
Market cap$666M$1.5B
Share price$24.21$51.02
Change, 1 year−16.8%−60.9%
Change, 5 years−75.2%−77.6%
Beta (5Y)0.490.82
Employees1,3001,300
StockData Score
Total score7 (better)6
Valuation score3 (better)0
Growth score03 (better)
Performance score11
Health score3 (better)2
Dividend score00
Valuation
P/S2.1× (better)3.3×
P/B0.7× (better)6.2×
FCF yield−15.6%−5.0% (better)
Fair value$45.28$32.23
Margin of safety46.5% (better)−58.3%
Growth
Revenue growth (TTM)6.8%25.4% (better)
Revenue growth, 5Y average−5.2%19.0% (better)
Net income growth (TTM)–−7665%
EPS growth (TTM)–−18300%
Profitability
Gross margin35.6%69.4% (better)
Operating margin−37.7%−20.3% (better)
Net margin−26.0%−23.4% (better)
FCF margin−32.0%−16.7% (better)
Return on equity−8.0% (better)−40.8%
Return on invested capital−10.9% (better)−36.2%
Financial health
Debt / equity0.00 (better)0.40
Interest coverage−1019.0×–
Current ratio6.34 (better)3.30
Altman Z-score5.25 (better)0.36
Piotroski F-score46 (better)
Dividends and buybacks
Buyback yield9.6%–
Shareholder yield9.6% (better)0.00%
Ownership
Held by institutions57.0%107%
Held by insiders39.5%–
Insider net buying, 12 months−$286K$91.2M (better)
Short interest, % of float12.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.